DE60134788D1 - Sulfone mit modulierender wirkung auf die gamma-sekretase - Google Patents
Sulfone mit modulierender wirkung auf die gamma-sekretaseInfo
- Publication number
- DE60134788D1 DE60134788D1 DE60134788T DE60134788T DE60134788D1 DE 60134788 D1 DE60134788 D1 DE 60134788D1 DE 60134788 T DE60134788 T DE 60134788T DE 60134788 T DE60134788 T DE 60134788T DE 60134788 D1 DE60134788 D1 DE 60134788D1
- Authority
- DE
- Germany
- Prior art keywords
- sulphones
- gamma secretase
- modulating effect
- secretase
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001174 sulfone group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Control Of El Displays (AREA)
- Radio Relay Systems (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0108592.7A GB0108592D0 (en) | 2001-04-05 | 2001-04-05 | Therapeutic agents |
| PCT/GB2001/003778 WO2002081433A1 (en) | 2001-04-05 | 2001-08-21 | Sulphones which modulate the action of gamma secretase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60134788D1 true DE60134788D1 (de) | 2008-08-21 |
Family
ID=9912330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60134788T Expired - Lifetime DE60134788D1 (de) | 2001-04-05 | 2001-08-21 | Sulfone mit modulierender wirkung auf die gamma-sekretase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7411004B2 (https=) |
| EP (1) | EP1379496B1 (https=) |
| JP (1) | JP2004531517A (https=) |
| AT (1) | ATE400550T1 (https=) |
| AU (1) | AU2001282313B2 (https=) |
| CA (1) | CA2442885C (https=) |
| DE (1) | DE60134788D1 (https=) |
| GB (1) | GB0108592D0 (https=) |
| WO (1) | WO2002081433A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) * | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| KR100927304B1 (ko) * | 2001-12-27 | 2009-11-18 | 다이이찌 세이야꾸 가부시기가이샤 | β-아밀로이드 단백 생산·분비 저해제 |
| DE10201392A1 (de) * | 2002-01-16 | 2003-07-31 | Bayer Ag | Phenylsulfoxide und-sulfone |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| DE10254875A1 (de) * | 2002-11-25 | 2004-06-03 | Bayer Healthcare Ag | Phenylsulfoxid und -sulfon-Derivate |
| GB0308318D0 (en) * | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| MXPA05012323A (es) * | 2003-05-16 | 2006-01-30 | Merck Sharp & Dohme | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. |
| PL379466A1 (pl) | 2003-06-30 | 2006-09-18 | Daiichi Sankyo Company , Limited | Heterocykliczne pochodne metylosulfonu |
| ZA200509613B (en) * | 2003-06-30 | 2007-05-30 | Daiichi Seiyaku Co | Heterocyclic methyl sulfone derivative |
| AR047666A1 (es) * | 2004-02-20 | 2006-02-01 | Merck Sharp & Dohme | Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido |
| AU2006234441B2 (en) | 2005-04-08 | 2011-07-07 | Daiichi Sankyo Company, Limited | Pyridylmethylsulfone derivative |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| EP2291181B9 (en) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine for the treatment of depression symptoms |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| PE20121172A1 (es) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | Piperidinas sustituidas con actividad en la hdm2 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020214834A1 (en) | 2019-04-19 | 2020-10-22 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12595248B2 (en) | 2019-12-17 | 2026-04-07 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| JP7595854B2 (ja) * | 2020-05-25 | 2024-12-09 | 地方独立行政法人大阪産業技術研究所 | ［６，６］メタノフラーレン誘導体の製造方法 |
| US20240116945A1 (en) | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| GEAP202516798A (en) | 2022-12-14 | 2025-10-27 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016403A (en) * | 1955-07-29 | 1962-01-09 | Searle & Co | 1-aryl-3-hydroxypropyl sulfones and processes |
| JPS537691A (en) * | 1976-07-09 | 1978-01-24 | Yoshitomi Pharmaceut Ind Ltd | Piperazines |
| DE2735314A1 (de) * | 1977-08-05 | 1979-02-22 | Basf Ag | Alpha-azolylsulfide und deren derivate |
| US4675316A (en) * | 1978-03-10 | 1987-06-23 | Rohm And Haas Company | Substituted azoylmethylarylsulfides and derivatives and pesticidal use thereof |
| DE2821829A1 (de) * | 1978-05-19 | 1979-11-22 | Basf Ag | Mittel zur regulierung des pflanzenwachstums |
| JPS5626847A (en) | 1979-08-13 | 1981-03-16 | Sagami Chem Res Center | Preparation of substituted salicylic acid derivative |
| JPS5716840A (en) * | 1980-07-03 | 1982-01-28 | Sagami Chem Res Center | Phneylacetic acid derivative |
| US4379921A (en) * | 1980-08-21 | 1983-04-12 | Sumitomo Chemical Company, Limited | Production of triazolylvinyl ketones |
| FR2593178B1 (fr) * | 1986-01-20 | 1988-04-29 | Esteve Labor Dr | Derives de 2-benzimidazolylalkylthio (ou sulfinyle ou sulfonyle) leur preparation et leur application en tant que medicaments. |
| JPS62181260A (ja) * | 1986-02-06 | 1987-08-08 | Nippon Kayaku Co Ltd | ピリジン誘導体およびそれを有効成分とする農園芸用殺菌剤 |
| JP3582070B2 (ja) * | 1994-08-11 | 2004-10-27 | 日本曹達株式会社 | フェニルエタン誘導体及びそれを用いた感熱記録材料 |
| JP2001505869A (ja) * | 1996-07-22 | 2001-05-08 | モンサント カンパニー | チオールスルホン メタロプロテアーゼ阻害剤 |
| US5703129A (en) | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| SE9901901D0 (sv) * | 1999-05-26 | 1999-05-26 | Astra Ab | Compounds |
| KR100927304B1 (ko) | 2001-12-27 | 2009-11-18 | 다이이찌 세이야꾸 가부시기가이샤 | β-아밀로이드 단백 생산·분비 저해제 |
| DE10201392A1 (de) | 2002-01-16 | 2003-07-31 | Bayer Ag | Phenylsulfoxide und-sulfone |
-
2001
- 2001-04-05 GB GBGB0108592.7A patent/GB0108592D0/en not_active Ceased
- 2001-08-21 EP EP01960923A patent/EP1379496B1/en not_active Expired - Lifetime
- 2001-08-21 US US10/473,767 patent/US7411004B2/en not_active Expired - Fee Related
- 2001-08-21 AT AT01960923T patent/ATE400550T1/de not_active IP Right Cessation
- 2001-08-21 WO PCT/GB2001/003778 patent/WO2002081433A1/en not_active Ceased
- 2001-08-21 AU AU2001282313A patent/AU2001282313B2/en not_active Ceased
- 2001-08-21 DE DE60134788T patent/DE60134788D1/de not_active Expired - Lifetime
- 2001-08-21 JP JP2002579421A patent/JP2004531517A/ja active Pending
- 2001-08-21 CA CA2442885A patent/CA2442885C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7411004B2 (en) | 2008-08-12 |
| ATE400550T1 (de) | 2008-07-15 |
| US20040082617A1 (en) | 2004-04-29 |
| EP1379496A1 (en) | 2004-01-14 |
| CA2442885A1 (en) | 2002-10-17 |
| EP1379496B1 (en) | 2008-07-09 |
| AU2001282313B2 (en) | 2008-01-10 |
| GB0108592D0 (en) | 2001-05-23 |
| WO2002081433A1 (en) | 2002-10-17 |
| JP2004531517A (ja) | 2004-10-14 |
| CA2442885C (en) | 2010-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60134788D1 (de) | Sulfone mit modulierender wirkung auf die gamma-sekretase | |
| ATE498608T1 (de) | Sulfone, die die aktivität von gamma-secretase modulieren | |
| CY1107116T1 (el) | Νεες κυκλοεξυλ σουλφονες | |
| DE59914996D1 (en) | Heterocyclisch substituierte amide als calpainhemmer | |
| DE60329533D1 (de) | Cyclische sulfamide zur inhibierung von gamma-sekretase | |
| DE60335731D1 (de) | Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer | |
| EA200400331A1 (ru) | Новые циклогексилсульфоны | |
| DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| GB0223040D0 (en) | Therapeutic compounds | |
| CY2014031I1 (el) | Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae | |
| DE122006000010I2 (de) | Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten | |
| BRPI0417006A (pt) | administração intraóssea local de agentes de formação de osso e agentes anti-reabsorção e dispositivos para a mesma | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| ATE345792T1 (de) | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
| ATE370770T1 (de) | Hautreinigungsmittel | |
| ATE386520T1 (de) | Kombination von riluzol und levodopa zur behandlung von morbus parkinson | |
| BR0317271A (pt) | Concentrado de suspensão em óleo | |
| ATE271390T1 (de) | Verwendung von azithromycin zur topischen behandlung von augeninfektionen | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| BR0108405A (pt) | Agente de ativação de célula | |
| ES2175356T3 (es) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares. | |
| FR2786100B1 (fr) | Nouvelle application therapeutique de la nicergoline | |
| ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |